Ad Header



The Pulse of the Pharmaceutical Industry

FDA approves Tesaro’s ovarian cancer drug

Written by: | | Dated: Monday, March 27th, 2017


The U.S. Food and Drug Administration on Monday approved Tesaro Inc’s drug, niraparib, for the treatment of recurrent ovarian cancer.

Epithelial ovarian, fallopian tube or primary peritoneal cancer affects the tissue covering the ovary or lining of the fallopian tube or abdominal wall.


(Reporting by Akankshita Mukhopadhyay in Bengaluru)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom